Sugi Predict

Sugi Predict / Compounds / SCHEMBL3515895

SCHEMBL3515895

SCHEMBL3515895

O=C(O)CCc1ccc(Br)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 3/20 0.55
▸ TSHR P16473 2/20 0.53
▸ ALDH1A1 P00352 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ FFAR4 Q5NUL3 1/20 0.45
▸ P4HTM Q9NXG6 1/20 0.42
▸ HSD17B10 Q99714 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ PPARG P37231 1/20 0.41
▸ NCOA2 Q15596 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ NCOR2 Q9Y618 1/20 0.41
▸ PDE5A O76074 1/20 0.40
▸ PDE9A O76083 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ KEAP1 Q14145 1/20 0.39
▸ GLS O94925 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15270538 0.89 TSHR (0.50) FFAR1TSHRALDH1A1KDM4EFFAR4
SCHEMBL27612554 0.86 TSHR (0.48) FFAR1TSHRALDH1A1KDM4EMAPT
SCHEMBL29308626 0.84 FPR2 (0.45) FFAR1TSHRALDH1A1KDM4ERAB9A
SCHEMBL5686 0.81 ALDH1A1 (0.52) TSHRALDH1A1KDM4EP4HTMMAPT
SCHEMBL18534286 0.80 CYP11B1 (0.48) TSHRALDH1A1KDM4EHSD17B10MAPT
SCHEMBL17841443 0.80 GBA1 (0.41) FFAR1TSHRALDH1A1KDM4EMAPT
SCHEMBL8414096 0.79 P4HTM (0.66) FFAR1FFAR4P4HTMKEAP1L3MBTL1
Hydrochloric Acid SCHEMBL3759897 0.79 ALDH1A1 (0.50) TSHRALDH1A1KDM4EP4HTMMAPT
SCHEMBL25007407 0.78 FFAR1 (0.55) FFAR1TSHRALDH1A1KDM4EP4HTM
SCHEMBL7996551 0.78 FFAR1 (0.55) FFAR1ALDH1A1FFAR4P4HTMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2024-07-04 — — US disclosed
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2024-07-04 — — US disclosed
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2024-07-04 — — US disclosed
CN-112543764-B Amide compound with BET proteolytic induction effect and medical application thereof 田边三菱制药株式会社 2024-05-10 — — CN disclosed
US-11931363-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2024-03-19 — — US disclosed
CN-116547270-A 4- (2-fluoro-4-methoxy-5-3- (((1-methylcyclobutyl) methyl) carbamoyl) bicyclo [2.2.1] hept-2-yl) carbamoyl) phenoxy) -1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as RXFP1 modulators for the treatment of heart failure 阿斯利康(瑞典)有限公司 2023-08-04 — — CN disclosed
US-20230139597-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2023-05-04 — — US disclosed
US-20230033320-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) 2023-02-02 — — US disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 — — US disclosed
EP-3954684-A1 PROCESS FOR THE PREPARATION OF HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS Ardelyx, Inc. (US) 2022-02-16 — — EP disclosed
US-9580437-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2017-02-28 — — US disclosed
US-9580437-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2017-02-28 — — US disclosed
WO-2016103155-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-30 — — WO disclosed
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-23 — — US disclosed
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-23 — — US disclosed
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-23 — — US disclosed
US-8183275-B2 Substituted imidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. (US) 2012-05-22 — — US disclosed
US-20100204236-A1 Substituted imidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. 2010-08-12 — — US disclosed
EP-2083623-A1 SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS Merck & Co., Inc. (US) 2009-08-05 — — EP disclosed
WO-2008051405-A1 SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS MERCK & CO., INC. (US) 2008-05-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11931363-B2 Triazolopyrimidine compounds and uses thereof EZH2, DOT1L, EED FFAR1 4181/4885TSHR 3300/4885ALDH1A1 529/4885
US-20100204236-A1 Substituted imidazoles as bombesin receptor subtype-3 modulators BRS3, GPR119, GIPR FFAR1 328/4885TSHR 238/4885ALDH1A1 4808/4885
US-20230139597-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS NR1H4, FXR1, GLP1R FFAR1 29/4885TSHR 19/4885ALDH1A1 2057/4885
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof BET1, BRD4, PHKB FFAR1 4563/4885TSHR 3428/4885ALDH1A1 4054/4885
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED FFAR1 4181/4885TSHR 3300/4885ALDH1A1 529/4885
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED FFAR1 4181/4885TSHR 3300/4885ALDH1A1 529/4885
US-20230033320-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED FFAR1 4181/4885TSHR 3300/4885ALDH1A1 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.